FibroGen Inc

14.44-0.1500-1.03%Vol 517.15K1Y Perf 21.38%
Aug 16th, 2022 16:00 DELAYED
BID13.73 ASK15.00
Open14.50 Previous Close14.59
Pre-Market- After-Market14.22
 - -  -0.22 -1.52%
Target Price
13.20 
Analyst Rating
Hold 3.29
Potential %
-8.59 
Finscreener Ranking
     35.79
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
+     37.48
Insiders Value % 3/6/12 mo.
-/-/-62 
Growth Ranking
     25.49
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-62 
Income Ranking
 —    -
Price Range Ratio 52W %
72.86 
Earnings Rating
Sell
Market Cap1.35B 
Earnings Date
8th Aug 2022
Alpha-0.01 Standard Deviation0.16
Beta0.80 

Today's Price Range

14.2014.56

52W Range

7.8116.91

5 Year PE Ratio Range

-31.40-26.70

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
-0.21%
1 Month
18.17%
3 Months
56.96%
6 Months
-3.60%
1 Year
21.38%
3 Years
-67.62%
5 Years
-64.78%
10 Years
-

TickerPriceChg.Chg.%
FGEN14.44-0.1500-1.03
AAPL173.03-0.1600-0.09
GOOG122.51-0.3700-0.30
MSFT292.71-0.7600-0.26
XOM91.46-0.8600-0.93
WFC46.060.31000.68
JNJ167.571.48000.89
FB196.640.99000.51
GE81.071.26001.58
JPM123.631.17000.96
 
ProfitabilityValueIndustryS&P 500US Markets
93.00
-83.80
-79.90
-217.90
-83.64
RevenueValueIndustryS&P 500US Markets
263.15M
2.81
1.68
8.28
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.94-0.7817.02
Q01 2022-0.84-0.6819.05
Q04 2021-0.68-1.45-113.24
Q03 20210.090.54500.00
Q02 2021-0.48-1.45-202.08
Q01 2021-0.90-0.7813.33
Q04 2020-0.29-0.64-120.69
Q03 2020-0.890.35139.33
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.94-16.05Negative
9/2022 QR-0.90-15.38Negative
12/2022 FY-3.39-4.31Negative
12/2023 FY-2.12-9.28Negative
Next Report Date-
Estimated EPS Next Report-0.94
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume517.15K
Shares Outstanding93.74K
Shares Float69.51M
Trades Count5.82K
Dollar Volume7.44M
Avg. Volume728.14K
Avg. Weekly Volume662.74K
Avg. Monthly Volume657.23K
Avg. Quarterly Volume864.45K

FibroGen Inc (NASDAQ: FGEN) stock closed at 14.44 per share at the end of the most recent trading day (a -1.03% change compared to the prior day closing price) with a volume of 517.15K shares and market capitalization of 1.35B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 531 people. FibroGen Inc CEO is Enrique A. Conterno.

The one-year performance of FibroGen Inc stock is 21.38%, while year-to-date (YTD) performance is 2.41%. FGEN stock has a five-year performance of -64.78%. Its 52-week range is between 7.81 and 16.91, which gives FGEN stock a 52-week price range ratio of 72.86%

FibroGen Inc currently has a PE ratio of -6.10, a price-to-book (PB) ratio of 13.09, a price-to-sale (PS) ratio of 5.20, a price to cashflow ratio of 12.50, a PEG ratio of 2.32, a ROA of -29.44%, a ROC of -77.99% and a ROE of -120.82%. The company’s profit margin is -83.64%, its EBITDA margin is -79.90%, and its revenue ttm is $263.15 Million , which makes it $2.81 revenue per share.

Of the last four earnings reports from FibroGen Inc, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.94 for the next earnings report. FibroGen Inc’s next earnings report date is -.

The consensus rating of Wall Street analysts for FibroGen Inc is Hold (3.29), with a target price of $13.2, which is -8.59% compared to the current price. The earnings rating for FibroGen Inc stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

FibroGen Inc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

FibroGen Inc has a Buy technical analysis rating based on Technical Indicators (ADX : 22.15, ATR14 : 0.72, CCI20 : 114.87, Chaikin Money Flow : 0.18, MACD : 0.77, Money Flow Index : 64.72, ROC : 12.23, RSI : 64.62, STOCH (14,3) : 93.36, STOCH RSI : 0.43, UO : 70.06, Williams %R : -6.64), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of FibroGen Inc in the last 12-months were: Thane Wettig (Buy at a value of $35 743), Thomas F. Kearns (Sold 13 100 shares of value $151 707 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
6 (85.71 %)
6 (85.71 %)
6 (100.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (14.29 %)
1 (14.29 %)
0 (0.00 %)
Summary RatingHold
3.29
Hold
3.29
Hold
3.00

FibroGen Inc

FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.

CEO: Enrique A. Conterno

Telephone: +1 415 978-1200

Address: 409 Illinois Street, San Francisco 94158, CA, US

Number of employees: 531

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

57%43%

Bearish Bullish

52%48%


News

Stocktwits